Outcomes of Beta-Lactam Allergic and Non-Beta-Lactam Allergic Patients with Intra-Abdominal Infection: A Case-Control Study
- PMID: 36551442
- PMCID: PMC9774689
- DOI: 10.3390/antibiotics11121786
Outcomes of Beta-Lactam Allergic and Non-Beta-Lactam Allergic Patients with Intra-Abdominal Infection: A Case-Control Study
Abstract
Background: In the case of intra-abdominal infections (IAI) in beta-lactam (BL) allergic patients, empiric antimicrobial therapy without BL is recommended; however, data regarding the outcome with alternative regimens are scarce. This study aimed to compare the outcomes of BL allergic (BLA) patients with IAI to those who were non-BLA (NBLA). Method: We conducted a case−control study in a French teaching hospital, between 1 January 2016 and 31 August 2021. BLA patients with IAI treated with fluoroquinolone or aztreonam and metronidazole were matched with controls treated with BL, on age, sex, disease severity, IAI localization, and healthcare-associated infection (HAI) status. We compared rates of therapeutic failures, adverse events, and HAI, and then assessed factors associated with therapeutic failure using a logistic regression model. Results: The therapeutic failure rate was 14% (p > 0.99) in both groups of 43 patients, and there was no significant difference in the adverse events rate (p > 0.99) and HAI rate (p = 0.154). Factors independently associated with therapeutic failure were higher BMI (OR 1.16; 95%CI [1.00−1.36]; p = 0.041), longer hospital length of stay (OR 1,20; 95%CI [1.08−1.41]; p = 0.006), and inadequate empiric antimicrobial therapy (OR 11.71; 95%CI [1.43−132.46]; p = 0.025). Conclusion: The outcomes of BLA patients with IAI treated without BL were the same as those for NBLA patients treated with BL.
Keywords: allergy; beta-lactam; intra-abdominal infection; outcomes; penicillin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Consequences of avoiding β-lactams in patients with β-lactam allergies.J Allergy Clin Immunol. 2016 Apr;137(4):1148-1153. doi: 10.1016/j.jaci.2015.10.026. Epub 2015 Dec 11. J Allergy Clin Immunol. 2016. PMID: 26688516
-
Effectiveness of empiric aztreonam compared to other beta-lactams for treatment of Pseudomonas aeruginosa infections.Infect Drug Resist. 2018 Oct 25;11:1975-1981. doi: 10.2147/IDR.S174570. eCollection 2018. Infect Drug Resist. 2018. PMID: 30464539 Free PMC article.
-
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Anti-Enterococcal Therapy for Intra-Abdominal Infection.Surg Infect (Larchmt). 2021 Mar;22(2):131-143. doi: 10.1089/sur.2020.001. Epub 2020 Jun 1. Surg Infect (Larchmt). 2021. PMID: 32471332
-
Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study.Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):587-599. doi: 10.1007/s13318-020-00625-5. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32440843
-
Fluoroquinolone-based versus β-lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.Int J Antimicrob Agents. 2019 Jun;53(6):746-754. doi: 10.1016/j.ijantimicag.2019.01.004. Epub 2019 Jan 10. Int J Antimicrob Agents. 2019. PMID: 30639629
Cited by
-
A rapid literature review of the impact of penicillin allergy on antibiotic resistance.JAC Antimicrob Resist. 2025 Jan 21;7(1):dlaf002. doi: 10.1093/jacamr/dlaf002. eCollection 2025 Feb. JAC Antimicrob Resist. 2025. PMID: 39840325 Free PMC article. Review.
-
Clinical Features and Outcomes of Enterococcal Bone and Joint Infections and Factors Associated with Treatment Failure over a 13-Year Period in a French Teaching Hospital.Microorganisms. 2023 May 5;11(5):1213. doi: 10.3390/microorganisms11051213. Microorganisms. 2023. PMID: 37317187 Free PMC article.
References
-
- Sakr Y., Jaschinski U., Wittebole X., Szakmany T., Lipman J., Ñamendys-Silva S.A., Martin-Loeches I., Leone M., Lupu M.-N., Vincent J.-L., et al. Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum Infect. Dis. 2018;5:ofy313. doi: 10.1093/ofid/ofy313. - DOI - PMC - PubMed
-
- Vogelaers D., Blot S., Van den Berge A., Montravers P. Abdominal Sepsis Study (‘AbSeS’) Group on behalf of the Trials Group of the European Society of Intensive Care Medicine Antimicrobial Lessons from a Large Observational Cohort on Intra-Abdominal Infections in Intensive Care Units. Drugs. 2021;81:1065–1078. doi: 10.1007/s40265-021-01534-w. - DOI - PubMed
-
- Montravers P., Dupont H., Leone M., Constantin J.-M., Mertes P.-M., Société Française D’anesthésie et de Réanimation (Sfar) Société de Réanimation de Langue Française (SRLF) Laterre P.-F., Misset B., Société de Pathologie Infectieuse de Langue Française (SPILF) et al. Guidelines for Management of Intra-Abdominal Infections. Anaesth. Crit. Care Pain Med. 2015;34:117–130. doi: 10.1016/j.accpm.2015.03.005. - DOI - PubMed
-
- Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J.C., Baron E.J., O’Neill P.J., Chow A.W., Dellinger E.P., Eachempati S.R., et al. Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 2010;50:133–164. doi: 10.1086/649554. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources